average a healthy adult heart beats about 100,000 times a day. Sometimes
however, problems arise with the electrical impulses that regulate the
heart. This causes an irregular heartbeat – or cardiac arrhythmia – a
condition where the heart beats significantly slower, faster or less
efficiently than normal. A person with a cardiac arrhythmia may
experience symptoms that can reduce quality of life and ultimately lead
to a risk of sudden death. Examples of cardiac arrhythmias include
supraventricular arrhythmias, ventricular tachycardia and atrial
Team The management of an irregular
heartbeat can span months or even years and include a variety of
treatments and procedural interventions. Lankenau Heart Institute’s
integrated approach to care allows electrophysiologists, cardiac
surgeons and advanced practitioners to work together to provide a
personalized treatment plan for each patient.
Approach Members of the Lankenau
Heart Institute’s cardiac
arrhythmia team are known worldwide for their experience in the
diagnosis and treatment of cardiac arrhythmias. They have made
significant contributions to the field through technological development
and their pioneering work has helped to advance new therapies and
As an international “show” site for leading medical
technology companies, Lankenau’s state-of-the-art
electrophysiology lab offers the latest integrated
mapping and imaging systems available. The pairing of
this sophisticated equipment with the skill and
experience of the cardiac arrhythmia team ensures
exceptional care for the full range of heart rhythm
To ensure the best care, the Lankenau Heart Institute
electrophysiology service offers 24-hour-a-day
monitoring using remote management technology for
patients who receive implantable devices (including
biventricular pacemakers and ICDs). This service alerts
our doctors to irregularities, premature battery
deficiency, and other cardiac events and allows them to
intervene quickly if a problem is detected.
Cardiac surgeons and electrophysiologists with the
Lankenau Heart Institute are experts in the use of
minimally invasive approaches to repair heart defects
leading to atrial fibrillation. Lankenau’s specialists
are among only a handful in the nation to offer the
AtriClip procedure which has proven effective in
treating atrial fibrillation and preventing stroke.
Through the innovative use of advanced integrated
mapping and imaging systems during surgical procedures,
they are achieving the best possible results for
Research & Clinical Trials
Lankenau Heart Institute’s electrophysiologists are committed to
providing patients with individualized care and more advanced treatment
options, including the latest clinical trials.
Points of Differentiation The
Lankenau Heart Institute’s cardiac arrhythmia program is widely
respected for its unique blend of experience, innovation and clinical
expertise. Its commitment to outcomes and patient care has led to
the following benefits:
State-of-the-art electrophysiology laboratories with the
most advanced technologies. This includes the verifiable
mapping of lesion sets when treating atrial fibrillation
(A-Fib) with surgical ablation, which has resulted in
greater than 88 percent of patients with persistent or
long-term A-Fib returning to normal rhythm.
An experienced and diverse team that is credentialed by
the Heart Rhythm Society and includes two
board-certified female electrophysiologists.
Lankenau Heart Institute electrophysiologists perform
more than 400 cardiac ablations and 700 device
implantations, making the program one of the busiest on
the East Coast.
The team cares for thousands of patients annually and
performs more than 1,000 cardiac arrhythmia procedures
each year. Through the collaboration of
cardiologists and heart
failure specialists the team ensures that patients
have access to the full spectrum of care.
A high degree of integration between electrophysiology
and other clinical specialties. Members of Lankenau’s
cardiac surgery team were the first in the region to use
EP lab equipment in the operating room to guide and test
the effectiveness of ablation lesions for the treatment
Infection rates that are between four and five times
below the national standard.
A commitment to developing novel treatment approaches
for biventricular pacing and ventricular tachycardia
Participation in groundbreaking clinical research such
as the LAPTOP-HF trial.
Ongoing efforts to advance the field on a national and
international stage through work with pharmaceutical and
device companies and the Food and Drug Administration.
For more information, call 1.866.CALL.MLH.